IN8bio Completes Treatment of First Cohort in Phase I Clinical Trial with Gamma Delta T-Cell Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme

IN8bio, Inc. announced an update from the ongoing Phase I clinical trial of INB-200, its DeltEx drug resistant immunotherapy , MGMT-gene modified gamma delta T-cells in patients with newly diagnosed GBM.